Answers are grounded in this paper and cite their sources.
: Ipilimumab leads to increased ALC, T cell count and T cell activation in malignant melanoma patients responding to treatment. A high baseline frequency of myeloid-derived suppressor cells and high levels of IL6 is associated with a reduced chance of responding to therapy.
No takes yet. Share an insight, caveat, or question.
Bjoern et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: